Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients

Journal of Virology

Volumn 84, Issue 9, 2010, Pages 4494-4503

  Kwon, So Young ^a,b   Park, Yong Kwang ^a,b   Ahn, Sung Hyun ^a   Cho, Eun Sook ^a   Choe, Won Hyeok ^a,b   Lee, Chang Hong ^a,b   Kim, Byung Kook ^a   Ko, Soon Young ^a   Choi, Hyo Sun ^a   Park, Eun Sook ^a,b   Shin, Gu Choul ^a,b   Kim, Kyun Hwan ^a,b  

^a Konkuk University School of Medicine   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CLEVUDINE; ENTECAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BLOOD SAMPLING; CASE REPORT; CLONE; DRUG DETERMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GENETIC CODE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; LONG TERM CARE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; TREATMENT DURATION; VIRUS CHARACTERIZATION; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA; SERUM; TREATMENT FAILURE; VIRAL PROTEINS;

CARNATION LATENT VIRUS; HEPATITIS B VIRUS;

EID: 77950821986     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02066-09     Document Type: Article

References (24)

1. Balakrishna Pai, S., S. H. Liu, Y. L. Zhu, C. K. Chu, and Y. C. Cheng. 1996. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methylbeta-L-arabinofuranosyl uracil. Antimicrob. Agents Chemother. 40:380-386.
2. Brunelle, M. N., A. C. Jacquard, C. Pichoud, D. Durantel, S. Carrouée-Durantel, J. P. Villeneuve, C. Trépo, and F. Zoulim. 2005. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41:1391-1398.
3. Chin, R., T. Shaw, J. Torresi, V. Sozzi, C. Trautwein, T. Bock, M. Manns, H. Isom, P. Furman, and S. Locarnini. 2001. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45:2495-2501.
4. Chu, C. K., T. Ma, K. Shanmuganathan, C. Wang, Y. Xiang, S. B. Pai, G. Q. Yao, J. P. Sommadossi, and Y. C. Cheng. 1995. Use of 2′-fluoro-5- methylbeta-L-ARABINOFURANOSYLURACIL AS A NOVEL ANTIVIRAL AGENT FOR HEPATITIS B VIRUS AND EPSTEIN-BARR VIRUS. ANTIMICROB. AGENTS CHEMOTHER. 39:979-981.
5. Delaney, W. E., IV, H. Yang, C. E. Westland, K. Das, E. Arnold, C. S. Gibbs, M. D. Miller, and S. Xiong. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77:11833-11841.
6. Fu, L., and Y. C. Cheng. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem. Pharmacol. 55:1567-1572.
7. Guarnieri, M., K. H. Kim, G. Bang, J. Li, Y. Zhou, X. Tang, J. Wands, and S. Tong. 2006. Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. J. Virol. 80:587-595. (Pubitemid 43062871)
8. Hoofnagle, J. H., E. Doo, T. J. Liang, R. Fleischer, and A. S. Lok. 2007. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45:1056-1075. (Pubitemid 46646501)
9. Kim, K. H., and B. L. Seong. 2003. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J. 22:2104-2116.
10. Ko, S. Y., S. Y. Kwon, W. H. Choe, B. K. Kim, K. H. Kim, and C. H. Lee. 2009. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study. Antivir. Ther. 4:585-590.
11. Lai, C. L., E. Gane, Y. F. Liaw, C. W. Hsu, S. Thongsawat, Y. Wang, Y. Chen, E. J. Heathcote, J. Rasenack, N. Bzowej, N. V. Naoumov, A. M. Di Bisceglie, S. Zeuzem, Y. M. Moon, Z. Goodman, G. Chao, B. F. Constance, and N. A. Brown for the Globe Study Group. 2007. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357:2576-2588.
12. Lai, C. L., J. Dienstag, E. Schiff, N. W. Leung, M. Atkins, C. Hunt, N. Brown, M. Woessner, R. Boehme, and L. Condreay. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
13. Lee, W. M. 1997. Hepatitis B virus infection. N. Engl. J. Med. 337:1733-1745.
14. Liaw, Y. F., J. J. Sung, W. C. Chow, G. Farrell, C. Z. Lee, H. Yuen, T. Tanwandee, Q. M. Tao, K. Shue, O. N. Keene, J. S. Dixon, D. F. Gray, and J. Sabbat. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351:1521-1531.
15. Lim, S. G., N. Leung, H. W. Hann, G. K. Lau, C. Trepo, H. Mommeja-Marin, C. Moxham, J. Sorbel, A. Snow, M. R. Blum, F. Rousseau, and P. Marcellin. 2008. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. 2008. Aliment. Pharmacol. Ther. 27:1282-1292.
16. Liu, S. H., K. L. Grove, and Y. C. Cheng. 1998. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob. Agents Chemother. 42:833-839.
17. Melegari, M., P. P. Scaglioni, and J. R. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633. (Pubitemid 28081083)
18. Ono, S. K., N. Kato, Y. Shiratori, J. Kato, T. Goto, R. F. Schinazi, F. J. Carrilho, and M. Omata. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 107:449-455.
19. Tenney, D. J., S. M. Levine, R. E. Rose, A. W. Walsh, S. P. Weinheimer, L. Discotto, M. Plym, K. Pokornowski, C. F. Yu, P. Angus, A. Ayres, A. Bartholomeusz, W. Sievert, G. Thompson, N. Warner, S. Locarnini, and R. J. Colonno. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48:3498-3507.
20. Tenney, D. J., R. E. Rose, C. J. Baldick, K. A. Pokornowski, B. J. Eggers, J. Fang, M. J. Wichroski, D. Xu, J. Yang, R. B. Wilber, and R. J. Colonno. 2009. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 49:1503-1514.
21. Warner, N., S. Locarnini, M. Kuiper, A. Bartholomeusz, A. Ayres, L. Yuen, and T. Shaw. 2007. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob. Agents Chemother. 51:2285-2292.
22. Yamamoto, T., S. Litwin, T. Zhou, Y. Zhu, L. Condreay, P. Furman, and W. S. Mason. 2002. Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil. J. Virol. 76:1213-1223. (Pubitemid 34066425)
23. Yoo, B. C., J. H. Kim, T. H. Kim, K. C. Koh, S. H. Um, Y. S. Kim, K. S. Lee, B. H. Han, C. Y. Chon, J. Y. Han, S. H. Ryu, H. C. Kim, K. S. Byun, S. G. Hwang, B. I. Kim, M. Cho, K. Yoo, H. J. Lee, J. S. Hwang, Y. S. Kim, Y. S. Lee, S. K. Choi, Y. J. Lee, J. M. Yang, J. W. Park, M. S. Lee, D. G. Kim, Y. H. Chung, S. H. Cho, J. Y. Choi, Y. O. Kweon, H. Y. Lee, S. H. Jeong, H. W. Yoo, and H. S. Lee. 2007. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 46:1041-1048.
24. Yoo, B. C., J. H. Kim, Y. H. Chung, K. S. Lee, S. W. Paik, S. H. Ryu, B. H. Han, J. Y. Han, K. S. Byun, M. Cho, H. J. Lee, T. H. Kim, S. H. Cho, J. W. Park, S. H. Um, S. G. Hwang, Y. S. Kim, Y. J. Lee, C. Y. Chon, B. I. Kim, Y. S. Lee, J. M. Yang, H. C. Kim, J. S. Hwang, S. K. Choi, Y. O. Kweon, S. H. Jeong, M. S. Lee, J. Y. Choi, D. G. Kim, Y. S. Kim, H. Y. Lee, K. Yoo, H. W. Yoo, and H. S. Lee. 2007. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 45:1172-1178.